Physician profile
Natalie Norem
NPI 1881923472
$1,242.51
in general payments reported to CMS, 2019-2025
25 companies · $261 in 2025
The $261 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $236 · 2023: $413 · 2024: $333 · 2025: $261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,006.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,006.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $231.81 | 2022-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Musculoskeletal Transplant Foundation INC. | $149.99 | 2023 | |
| Amgen INC. | $109.13 | 2023-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $79.43 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $78.25 | 2024-2025 | Gardasil 9, Capvaxive, Delstrigo |
| Novartis Pharmaceuticals Corporation | $67.77 | 2022-2023 | |
| Xeris Pharmaceuticals, INC. | $63.27 | 2023-2025 | Gvoke Hypopen |
| Astrazeneca Pharmaceuticals LP | $52.01 | 2024 | Airsupra |
| Abbvie INC. | $49.11 | 2022-2024 | |
| Solventum Corporation | $43.54 | 2024 | Silvercel, 3m Coban, Tegaderm |
| Edwards Lifesciences Corporation | $32.83 | 2025 | Sapien 3 Ultra Resilia |
| Pacira Pharmaceuticals Incorporated | $30.23 | 2025 | Exparel |
| Sunovion Pharmaceuticals INC. | $23.79 | 2022 | |
| Viiv Healthcare Company | $23.75 | 2022 | |
| Masimo Corporation | $23.54 | 2023 | Set and Rainbow Set |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $22.09 | 2023 | Watchman Access System |
| Dynavax Technologies Corporation | $21.45 | 2022 | |
| Lilly USA, LLC | $20.58 | 2024 | Mounjaro |
| Exact Sciences Corporation | $20.40 | 2024 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $20.35 | 2023 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.22 | 2023 | Trulance, Xifaxan |
| Novo Nordisk INC | $16.41 | 2024 | Wegovy |
| Sanofi-Aventis U.S. LLC | $15.49 | 2025 | |
| Phadia US INC. | $13.78 | 2022 | |
| Smith+Nephew, INC. | $13.29 | 2023 | Collagenase Santyl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Norem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.